TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement